NCT04516317View on ClinicalTrials.gov

Very Severe Malaria Treated by Intravenous Artesunate

CompletedOBSERVATIONAL
Enrollment

578

Participants

Timeline

Start Date

August 10, 2020

Primary Completion Date

March 15, 2022

Study Completion Date

March 22, 2022

Conditions
Severe Malaria
Interventions
OTHER

None (Observational study Group intravenous artesunate)

Retrospective descriptive study of Group intravenous artesunate

OTHER

None (Observational study Group intravenous quinine)

Retrospective descriptive study of Group intravenous quinine

Trial Locations (1)

78150

Fabrice BRUNEEL, Le Chesnay

All Listed Sponsors
lead

Dr Fabrice BRUNEEL

OTHER

NCT04516317 - Very Severe Malaria Treated by Intravenous Artesunate | Biotech Hunter | Biotech Hunter